Marker Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The MAR-T platform offers a first-in-class, multi-antigen T-cell therapy with strong safety and efficacy in lymphoma, showing high response rates and durable outcomes in heavily pretreated patients. Expansion into solid tumors and off-the-shelf products is underway, supported by significant non-dilutive funding.
Fiscal Year 2025
-
Multi-TAA T-cell therapy shows promise in DLBCL and solid tumors, with strong safety and efficacy in heavily pretreated patients. Manufacturing is streamlined, and pivotal trials are planned for early next year, with off-the-shelf and solid tumor programs advancing.
-
MT-601 demonstrated a 50% complete response rate and 66% overall response rate in heavily pretreated non-Hodgkin lymphoma patients, with durable responses and an excellent safety profile, even at the highest tested dose. The therapy addresses significant unmet needs in relapsed/refractory lymphoma, especially after CAR T and bispecific antibody failures.
-
MAR-T cell therapy targets multiple tumor antigens without genetic modification, showing strong response rates and a favorable safety profile in lymphoma. The lead asset MT-601 is advancing in both hematologic and solid tumors, supported by robust manufacturing and government funding.